Results 141 to 150 of about 2,193 (158)

Pretomanid for the treatment of drug resistant pulmonary tuberculosis: a comprehensive review

Archives of Microbiology
Pretomanid, a novel nitroimidazoles or nitroimidazooxazines, was recently approved as part of BPaL (Bedaquiline, Pretomanid, and Linezolid) regimen for treating extensively drug-resistant (XDR) and treatment-intolerant/ nonresponsive multidrug-resistant (MDR) cases of pulmonary tuberculosis (TB).
Roopendra, Kumar, Jagdeep Singh, Sohal, Ajay Vir, Singh, Devendra Singh, Chauhan   +3 more
openaire   +2 more sources

Pretomanid can significantly increase plasma rivaroxaban concentrations—a case report

European Journal of Clinical Pharmacology
Rivaroxaban, a direct factor Xa inhibitor, is an oral anticoagulant used in the prevention and treatment of thromboembolic disease. The clearance of rivaroxaban involves excretion unchanged via the kidneys where it is subject to active secretion into the renal tubules, involving P-glycoprotein (P-gp) and organic anion transporter 3 (OAT3).
Dali Fan, Teurai Chikura, Sarah McCrostie, Paul Chin   +3 more
openaire   +2 more sources

Pretomanid (antituberculoso nuevo) análisis retrosintético

2022
Torres, Hector, La Parra, Mario González-De   +1 more
openaire   +1 more source

Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis

Antimicrobial Agents and Chemotherapy, 2021
Elisa H Ignatius, Mahmoud Tareq Abdelwahab, Nikhil Gupte   +2 more
exaly  

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

Journal of Antimicrobial Chemotherapy, 2022
Julio Ortiz Canseco, Timothy D Mchugh, Silke Feuerriegel   +2 more
exaly  

Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study

Pulmonary Pharmacology and Therapeutics, 2022
Kexin Li
exaly  

Delamanid/Pretomanid (antituberculosos nuevos) síntesis introducción

2022
La Parra, Mario González-De, Torres, Hector   +1 more
openaire   +1 more source

Π-Π interactions stabilize PeptoMicelle-based formulations of Pretomanid derivatives leading to promising therapy against tuberculosis in zebrafish and mouse models

Journal of Controlled Release, 2023
Kerstin Johann
exaly  

Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis

The Lancet Respiratory Medicine
Sarah M, Labuda, Barbara, Seaworth, Shom, Dasgupta, Neela D, Goswami   +3 more
openaire   +2 more sources

Bedaquiline/Linezolid/Pretomanid

Reactions Weekly
openaire   +2 more sources